Contineum Therapeutics plans to spend most of its IPO cash on clinical testing of a lead drug candidate in development for idiopathic pulmonary fibrosis and multiple sclerosis. This small molecule blocks a competitive target pursued by several other companies, including Bristol Myers Squibb and AbbVie.
Contineum Therapeutics, which emerged from a Verant Ventures startup creation engine, has filed paperwork for an IPO. The biotech’s clinical-stage pipeline spans multiple sclerosis, idiopathic pulmonary fibrosis, and depression.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
FibroGen drug pamrevlumab has failed a Phase 3 study testing it in the chronic lung disorder idiopathic pulmonary fibrosis. It’s the second trial failure for the drug in the past month and the company’s third Phase 3 failure in the past two months.
AbbVie acquired DJS Antibodies for $255 million up front. The U.K.-based biotech’s lead program is an antibody drug in preclinical development for idiopathic pulmonary fibrosis, a chronic lung disorder with few FDA-approved treatments.
Endeavor BioMedicines aims to kill two birds with one stone—that stone being a small molecule drug. Taladegib targets a cell signaling pathway associated with both cancer and idiopathic pulmonary fibrosis, and the biotech will apply its Series B round toward clinical tests of the molecule on both fronts.
A NeRRE Therapeutics drug that failed a clinical trial for refractory or unexplained chronic cough is getting a second shot as a potential treatment for chronic cough in patients with idiopathic pulmonary fibrosis, a rare lung disorder. The biotech raised £20M to proceed with Phase 2 testing.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The collaboration includes six drugs in development and more than 20 in preclinical development. It also amends an existing four-year-old partnership the two companies had regarding the autoimmune disease drug filgotinib.
Health tech incubator MATTER has joined forces with Three Lakes Partners to launch an innovation challenge to meet the needs of idiopathic pulmonary fibrosis patients.
It plans to bring its idiopathic pulmonary fibrosis small molecule to the clinic in the next two years.
#MIS2014 Innovation #5 – antibody drug conjugates. Again! Idea around for 30 years, but antibodies better, humanized, understand targets. — Meghana Keshavan (@meghanakeshavan) October 29, 2014 The Cleveland Clinic just announced its top 10 medical innovations for 2015 – a long anticipated and often-prescient listing of the most gamechanging new health techs. This just in: […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
MedCity News has partnered with BioCrossroads to provide coverage focused on Indiana’s next generation of growth and innovation in life sciences. Indianapolis startup ImmuneWorks is developing drugs to treat lung transplant patients, idiopathic pulmonary fibrosis and other fibrotic lung diseases. The 8-year-old company was founded by two researchers at the Indiana University School of Medicine […]